Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1

Caucheteux, Stephan M.; Mitchell, John P.; Ivory, Matthew Owen; Hirosue, Sachiko; Hakobyan, Svetlana; Dolton, Garry; Ladell, Kristin; Miners, Kelly L.; Price, David A.; Kan‐Mitchell, June; Sewell, Andrew K.; Nestle, Frank O.; Moris, Arnaud; Karoo, R.O.S.; Birchall, James Caradoc; Swartz, Melody A.; Hubbel, Jeffrey A.; Blanchet, Fabien P.; Piguet, Vincent

doi:10.1016/j.jid.2016.01.033

Cited by 17 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2014, the authors showed that adjuvant‐loaded (i.e., CpG ODNs or paclitaxel, a TLR4 agonist) PPS nanoparticles without antigens can target CD11c + dendritic cells in lymph nodes presumably bathed in tumor antigens and mount a potent antitumor response . More recently, Piguet and co‐workers administered p24 Gag peptide‐conjugated PPS nanoparticles to vaccinate against HIV‐1 . In combination with their ability to degrade in ROS‐heavy environments (e.g., solid tumors), these works suggest that PPS is a promising biomaterial for stimuli‐responsive antigen and adjuvant delivery.…”

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…HIV‐1 vaccine development has demonstrated that coating nanoparticles in the p24 antigen of HIV‐1 allows targeted delivery into the dermis, eliciting a strong, HIV‐1‐specific CD4 + T‐cell response and B‐cell antibody production (Caucheteux et al, ). Exploiting the mechanics of VS formation has led to the development of ganglioside GM3 membrane‐wrapped gold nanoparticles that were found to activate GM3‐CD169 trafficking pathway in mDC.…”

Section: Nanoparticles To Mimick Viruses: Potential Therapeutic Targets?mentioning

confidence: 99%

Masters of manipulation: Viral modulation of the immunological synapse

Bayliss

Piguet

2018

Cellular Microbiology

Self Cite

View full text Add to dashboard Cite

In order to thrive, viruses have evolved to manipulate host cell machinery for their own benefit. One major obstacle faced by pathogens is the immunological synapse. To enable efficient replication and latency in immune cells, viruses have developed a range of strategies to manipulate cellular processes involved in immunological synapse formation to evade immune detection and control T-cell activation. In vitro, viruses such as human immunodeficiency virus 1 and human T-lymphotropic virus type 1 utilise structures known as virological synapses to aid transmission of viral particles from cell to cell in a process termed trans-infection. The formation of the virological synapse provides a gateway for virus to be transferred between cells avoiding the extracellular space, preventing antibody neutralisation or recognition by complement. This review looks at how viruses are able to subvert intracellular signalling to modulate immune function to their advantage and explores the role synapse formation has in viral persistence and cell-to-cell transmission.

show abstract

“…Therefore, targeting the delivery of antigens to DLNs and controlling antigen uptake to specific APCs within them should be an effective approach for vaccinology. To improve CTL activation via DLN targeting, various antigen delivery carriers such as liposomes 7 , polymer nanoparticles 8 , polymer microparticles 9 , 10 , polymersomes 11 , 12 and hydrogels 13 have been developed 14 . The efficiency of transfer from the injection site to the lymph nodes depends on the size and rigidity of the nanoparticles 15 – 17 .…”

Section: Introductionmentioning

confidence: 99%

Structural effects and lymphocyte activation properties of self-assembled polysaccharide nanogels for effective antigen delivery

Miura

Tahara

Sawada

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The success of immunotherapeutic vaccines is often limited by their inability to activate the cytotoxic T lymphocyte (CTL)-inducing Th1 pathway. We investigated the ability of self-assembled nanogels (CHP or CH-CDex) to activate this pathway, and characterised them chemically and biologically. Once loaded with antigen (ovalbumin, OVA) their OVA encapsulation and dissociation rates suggested the possibility of effective antigen delivery. The DC2.4 dendritic cell line took up either vaccine time-dependently, but both vaccines required CpG DNA for class I MHC presentation. The nanogel vaccines interacted with RAW264.7, a Balb/c mouse-derived macrophage cell line, and co-localised with lysosomes, suggesting their endocytotic internalization in RAW264.7. Both vaccines activated CTLs better than OVA alone. Unlike OVA alone, the nanogel vaccines induced IgG2a antibody production in mice, whereas the former induced IgG1 antibodies. OVA-nanogel delivery to the draining lymph nodes (DLNs) was higher than that for OVA alone, reaching a deeper medullary area. Furthermore, Langerin+ CD103+ DCs interacted with the nanogel vaccines effectively, which is a subset of cross-presentation DC, in the DLNs. The nanogel vaccines each had good anti-tumour efficacy in OVA tumour-bearing mice compared with the OVA alone. Thus, CHP and CH-CDex nanogels should be investigated further because of the great potential they offer for immunotherapy.

show abstract

Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1

Cited by 17 publications

References 39 publications

Materials for Immunotherapy

Materials for Immunotherapy

Masters of manipulation: Viral modulation of the immunological synapse

Structural effects and lymphocyte activation properties of self-assembled polysaccharide nanogels for effective antigen delivery

Contact Info

Product

Resources

About